BriLife

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for central nervous system (CNS) disorders and infectious diseases. The company's lead program, NRX-101, is a fixed-dose combination of D-cycloserine and lurasidone targeting suicidal bipolar depression and chronic pain. NRx gained significant attention for its partnership with the Israel Institute for Biological Research (IIBR) to develop and commercialize BriLife, a self-propagating live-virus vaccine against COVID-19. While the company has shifted its primary focus back to its CNS pipeline, it continues to explore specialized applications for its viral vector technology. NRx is publicly traded on the Nasdaq and maintains a strategic focus on high-unmet-need psychiatric and respiratory conditions.